Microbial Biomarkers in Liquid Biopsy for Cancer: An Overview and Future Directions

Overview

Journal Cancer Control

Specialty Oncology

Date 2024 Oct 21

PMID 39431347

Authors

Feiyang Luo

Xinyue Wang

Chun Ye

Haitao Sun

Affiliations

Soon will be listed here.

Abstract

In recent years, the relationship between microbes and tumors has led to a new wave of scholarly pursuits. Due to the growing awareness of the importance of microbiota, including those within tumors, for cancer onset, progression, metastasis, and treatment, researchers have come to understand that microbiota and the tumor microenvironment together form a dynamic and complex ecosystem. Liquid biopsy technology, a non-invasive and easily repeatable method for sample collection, combined with emerging multi-omics techniques, allows for a more comprehensive and in-depth exploration of microbial signals and characteristics in bodily fluids. Microbial biomarkers hold immense potential in the early diagnosis, treatment stratification, and prognosis prediction of cancer. In this review, we describe the significant potential of microbial biomarkers in liquid biopsy for clinical applications in cancer, including early diagnosis, predicting treatment responses, and prognosis. Moreover, we discuss current limitations and potential solutions related to microbial biomarkers. This review aims to provide an overview and future directions of microbial biomarkers in liquid biopsy for cancer clinical practice.

References

You L, Zhou J, Xin Z, Hauck J, Na F, Tang J . Novel directions of precision oncology: circulating microbial DNA emerging in cancer-microbiome areas. Precis Clin Med. 2022; 5(1):pbac005. PMC: 9026200. DOI: 10.1093/pcmedi/pbac005. View

Bullman S, Pedamallu C, Sicinska E, Clancy T, Zhang X, Cai D . Analysis of persistence and antibiotic response in colorectal cancer. Science. 2017; 358(6369):1443-1448. PMC: 5823247. DOI: 10.1126/science.aal5240. View

Daniluk J, Daniluk U, Rogalski P, Dabrowski A, Swidnicka-Siergiejko A . Microbiome-Friend or Foe of Pancreatic Cancer?. J Clin Med. 2021; 10(23). PMC: 8658245. DOI: 10.3390/jcm10235624. View

Cogdill A, Gaudreau P, Arora R, Gopalakrishnan V, Wargo J . The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. Trends Immunol. 2018; 39(11):900-920. DOI: 10.1016/j.it.2018.09.007. View

Flemer B, Warren R, Barrett M, Cisek K, Das A, Jeffery I . The oral microbiota in colorectal cancer is distinctive and predictive. Gut. 2017; 67(8):1454-1463. PMC: 6204958. DOI: 10.1136/gutjnl-2017-314814. View

Qiao H, Tan X, Li H, Li J, Chen X, Li Y . Association of Intratumoral Microbiota With Prognosis in Patients With Nasopharyngeal Carcinoma From 2 Hospitals in China. JAMA Oncol. 2022; 8(9):1301-1309. PMC: 9284409. DOI: 10.1001/jamaoncol.2022.2810. View

Mishra S, Tejesvi M, Hekkala J, Turunen J, Kandikanti N, Kaisanlahti A . Gut microbiome-derived bacterial extracellular vesicles in patients with solid tumours. J Adv Res. 2024; 68:375-386. PMC: 11785572. DOI: 10.1016/j.jare.2024.03.003. View

Erdbrugger U, Blijdorp C, Bijnsdorp I, Borras F, Burger D, Bussolati B . Urinary extracellular vesicles: A position paper by the Urine Task Force of the International Society for Extracellular Vesicles. J Extracell Vesicles. 2021; 10(7):e12093. PMC: 8138533. DOI: 10.1002/jev2.12093. View

Pushalkar S, Hundeyin M, Daley D, Zambirinis C, Kurz E, Mishra A . The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018; 8(4):403-416. PMC: 6225783. DOI: 10.1158/2159-8290.CD-17-1134. View

10.

Zhou X, You L, Xin Z, Su H, Zhou J, Ma Y . Leveraging circulating microbiome signatures to predict tumor immune microenvironment and prognosis of patients with non-small cell lung cancer. J Transl Med. 2023; 21(1):800. PMC: 10636862. DOI: 10.1186/s12967-023-04582-w. View

11.

Yagin F, Alkhateeb A, Colak C, Azzeh M, Yagin B, Rueda L . A Fecal-Microbial-Extracellular-Vesicles-Based Metabolomics Machine Learning Framework and Biomarker Discovery for Predicting Colorectal Cancer Patients. Metabolites. 2023; 13(5). PMC: 10222315. DOI: 10.3390/metabo13050589. View

12.

Fu K, Cheung A, Wong C, Liu W, Zhou Y, Wang F . Streptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice. Cell. 2024; 187(4):882-896.e17. DOI: 10.1016/j.cell.2024.01.004. View

13.

Bebelman M, Smit M, Pegtel D, Baglio S . Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018; 188:1-11. DOI: 10.1016/j.pharmthera.2018.02.013. View

14.

Cho E, Leem S, Kim S, Yang J, Lee Y, Kim S . Circulating Microbiota-Based Metagenomic Signature for Detection of Hepatocellular Carcinoma. Sci Rep. 2019; 9(1):7536. PMC: 6525191. DOI: 10.1038/s41598-019-44012-w. View

15.

Dai J, Tan X, Qiao H, Liu N . Emerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets. Protein Cell. 2023; 15(4):239-260. PMC: 10984626. DOI: 10.1093/procel/pwad052. View

16.

Rubinstein M, Wang X, Liu W, Hao Y, Cai G, Han Y . Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013; 14(2):195-206. PMC: 3770529. DOI: 10.1016/j.chom.2013.07.012. View

17.

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W . Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019; 178(4):795-806.e12. PMC: 7288240. DOI: 10.1016/j.cell.2019.07.008. View

18.

Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D . Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019; 7(1):193. PMC: 6651993. DOI: 10.1186/s40425-019-0650-9. View

19.

Cao Y, Oh J, Xue M, Huh W, Wang J, Gonzalez-Hernandez J . Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites. Science. 2022; 378(6618):eabm3233. PMC: 9993714. DOI: 10.1126/science.abm3233. View

20.

Park E, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo J . Targeting the gut and tumor microbiota in cancer. Nat Med. 2022; 28(4):690-703. DOI: 10.1038/s41591-022-01779-2. View